Lords Mark Industries Limited, a Maharashtra-based small-cap company, announced plans to begin commercial sales of its in vitro diagnostics (IVD) products in the UK starting December 2026, advancing its timeline by two months. The company’s shares rose nearly 2.57% on Monday, closing close to their upper circuit level following the update, according to livemint.com.
The company recently achieved a key milestone by registering its IVD portfolio with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This registration expands Lords Mark Industries’ international footprint beyond its AI-powered haemodialysis system, which had secured MHRA approval in September. The registration enables the firm to strengthen its healthcare and diagnostics presence across the UK and allied markets, the report said.
This move broadens Lords Mark Industries’ international roadmap from renal-care technology into a wider diagnostics and healthcare portfolio. The UK market is seen as a strategic platform for the company’s global expansion ambitions. The MHRA registration is a critical regulatory step that supports the company’s plans to capitalize on growing demand for healthcare technologies in the region, according to livemint.com.
Lords Mark Industries’ accelerated commercial launch in December 2026 positions it to enter the UK healthcare diagnostics market ahead of schedule, potentially enhancing its competitive standing. The company views the UK and allied markets as key to its broader international growth strategy, as detailed in its recent business update.